Actively Recruiting
Study to Evaluate Safety and Effects of BBT002 in Healthy Adults and Adults With Chronic Rhinosinusitis with Nasal Polyps, With or Without Asthma
Led by Bambusa Therapeutics · Updated on 2026-07-22
64
Participants Needed
12
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BBT002, a drug being studied for its safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and clinical activity in healthy volunteers and people with Chronic Rhinosinusitis with Nasal Polyps CRSwNP, with or without asthma. This randomized, double-blind, placebo-controlled study includes participants from 18 to 75 years old and aims to understand how BBT002 behaves in the body and its effects on these conditions. The study has two parts Part A involves a single dose of BBT002 or placebo given to healthy volunteers in increasing dose groups. Part B includes patients with CRSwNP, with or without asthma, who receive five repeated doses of BBT002 or placebo. The doses are given sequentially, and the study monitors participants for safety and drug activity over time. Participants will undergo various assessments including monitoring for adverse events, vital signs, physical exams, laboratory tests, and ECG readings up to 141 days after a single dose in healthy volunteers and up to 169 days after the first dose in patients. Researchers will also measure how the drug is processed in the body and check for immune responses. The total study duration extends until June 2028, ensuring comprehensive evaluation throughout the treatment and follow-up periods.
CONDITIONS
Brief Title
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma
Research Team
T
Tracy Ji, Senior study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here